This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform.
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.
Zacks.com featured highlights Fox, Universal Technical Institute, Pfizer, Tenet Healthcare and Newmont
by Zacks Equity Research
Fox, Universal Technical Institute, Pfizer, Tenet Healthcare and Newmont have been highlighted in this Screen of The Week article.
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
by Zacks Equity Research
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates. Stock declines.
Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts
by Zacks Equity Research
MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
by Sanghamitra Saha
Top-ranked stocks Fox (FOXA), Universal Technical Institute (UTI), Pfizer (PFE), Tenet Healthcare (THC) and Newmont (NEM) are likely to beat on the bottom line in their upcoming releases.
Zacks.com featured highlights Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander
by Zacks Equity Research
Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander have been highlighted in this Screen of The Week article.
Company News for Apr 30, 2025
by Zacks Equity Research
Companies In The News Are: NUE, REGN, PYPL, PFE.
Boost Your Portfolio With These 5 Low Price-to-Book Stocks
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, MD, PFE, STNE and SAN are some such stocks.
Is Healthcare Losing the Status of Safe Haven? ETFs in Focus
by Sanghamitra Saha
Healthcare stocks face new risks under Trump, despite their usual defensive reputation.
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
by Shaun Pruitt
Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales
by Zacks Equity Research
PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge.
Trade Balance in Goods Hits All-Time Record, Plus Q1 Earnings
by Mark Vickery
Pre-market futures are mixed-to-flat once again, this time with the blue-chip Dow leading into positive territory.
Compared to Estimates, Pfizer (PFE) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
by Zacks Equity Research
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance. Share price rises.
Pfizer (PFE) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 43.75% and 0.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron
by Zacks Equity Research
Pfizer, Eli Lilly, Amgen, Biogen and Regeneron are included in this Analyst Blog.
Zacks.com featured highlights StoneCo, Carriage Services, Associated Banc-Corp and Pfizer
by Zacks Equity Research
StoneCo, Carriage Services, Associated Banc-Corp and Pfizer have been highlighted in this Screen of The Week article.
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock.
4 Top Value Stocks to Invest in as US-Global Trade Talks Unfold
by Sumit Singh
Value investing is essentially about selecting cheap but fundamentally sound stocks. STNE, CSV, ASB & PFE boast low P/CF ratios.
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?
by Zacks Equity Research
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?